Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Costs and economics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

This modeling study projects that the financial toll of Alzheimer's and related dementias will grow very unevenly by race and ethnicity in the US. While white families currently bear the largest dollar burden overall, the combined burden on Black and Latino families is projected to grow much faster, driven largely by unpaid family caregiving, and Latino caregivers already lose a much larger share of household income to caregiving than white or Black caregivers do.

What this study adds

Evidence grade: Moderate

The record lists 31,028 participants. This modeling study projects that the financial toll of Alzheimer's and related dementias will grow very unevenly by race and ethnicity in the US, with the combined burden on Black and Latino families projected to grow much faster than that on white families. Its stated limit: Long-horizon (40-year) projections rely on multiple linked survey data sources and assumptions about future demographic, wage, and cost trends that carry substantial uncertainty.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mudrazija, S., Aranda, M. P., Gaskin, D. J., Monroe, S., & Richard, P. (2025). Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060. JAMA Network Open.

Vancouver

Mudrazija S, Aranda MP, Gaskin DJ, Monroe S, Richard P. Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060. JAMA Network Open. 2025. PMID: 40471578.

BibTeX

@article{mudrazija2025-89faa596,
  author  = {Mudrazija, S. and Aranda, M. P. and Gaskin, D. J. and Monroe, S. and Richard, P.},
  title   = {{Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060}},
  journal = {JAMA Network Open},
  year    = {2025},
  pmid    = {40471578}
}

Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This modeling study projects that the financial toll of Alzheimer's and related dementias will grow very unevenly by race and ethnicity in the US, with the combined burden on Black and Latino families projected to grow much faster than that on white families. Latino caregivers already lose a much larger share of household income to caregiving than white or Black caregivers do.

Study details

Limitations

Long-horizon (40-year) projections rely on multiple linked survey data sources and assumptions about future demographic, wage, and cost trends that carry substantial uncertainty.

How this study scored 61/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record left out, no data; Study design 3 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 0 of 2; Free to read left out, no data. 38 of the 62 points it could be judged on, which is 61 of 100. Total 61 of 100.38 of the 62 points we could judge = 61 of 100

Published in a leading specialty journal, and it is a computer model rather than new measurements. Scored zero for randomized / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 38 of the 62 points we could judge it on, which is 61 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA Network Open)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 3 / 12 A computer model rather than new measurements
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 31,028 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 0 / 2 No PubMed ID and no DOI — scores zero (not stated in the record — scored 0)
Free to read — / 2 Access not recorded — left out of this score
Points 38 / 62 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 38 of the 62 points we could judge it on is 61 out of 100.
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Costs and economics from nearby years

Also in Costs and economics

21 studies in the library are filed under Costs and economics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Costs and economics hub.

Similar studies

More on Costs and economics

See all studies in Costs and economics →